|
Press Releases |
|
 |
|
Tuesday, April 4, 2023 |
|
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal |
Eisai Co., Ltd. today announced an article about long-term health outcomes of anti-amyloid-beta (Aβ) protofibril* antibody lecanemab in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) using simulation modeling was published in the peer-reviewed journal Neurology and Therapy. more info >> |
|
Monday, April 3, 2023 |
|
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System |
Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system. more info >> |
|
Friday, March 31, 2023 |
|
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting |
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL). more info >> |
|
Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals |
Eisai Co., Ltd. and Biogen Inc. announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD), were published in the peer-reviewed journals. more info >> |
|
Friday, March 24, 2023 |
|
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer |
Eisai Co., Ltd. announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28. more info >> |
|
Thursday, March 23, 2023 |
|
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting |
Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI), Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD). more info >> |
|
Monday, March 20, 2023 |
|
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal |
Eisai Co., Ltd. today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril antibody lecanemab (generic name, U.S. brand name: LEQEMBI) in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). more info >> |
|
Tuesday, March 14, 2023 |
|
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease |
Eisai Co., Ltd. announced today that the U.S. Veterans' Health Administration (VHA) is providing coverage of LEQEMBI (lecanemab-irmb) to veterans living with early stages of Alzheimer's disease (AD). VHA healthcare professionals meeting the criteria set forth by the VHA can prescribe LEQEMBI to veterans who fit the VHA's criteria and the U.S. Food and Drug Administration's (FDA) current label. more info >> |
|
Friday, March 10, 2023 |
|
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award |
Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win). more info >> |
|
Thursday, March 9, 2023 |
|
Eisai Certified as a 2023 Health and Productivity Management Outstanding |
Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Kingnet Acquired Type 4 and Type 9 Licenses: Continuously Broadening Business Boundaries and Advancing Global Expansion Layout
Jul 14, 2025 23:47 HKT/SGT
|
|
|
Graphene Aluminium Ion Battery Patent Granted and GMG and The University of Queensland Enter into New Collaboration Agreement
Jul 14, 2025 20:09 HKT/SGT
|
|
|
BlockBits Launches a Futures Trading Service, Offering Traders a Wide Range of Advanced Tools
Jul 14, 2025 20:00 HKT/SGT
|
|
|
XDS Datacentres signs 15-year deal to host 10MW of AI workloads in Saudi's Desert Dragons facilities
Jul 14, 2025 17:00 HKT/SGT
|
|
|
Buy International Homes at the Global Property Expo, Singapore
Jul 14, 2025 14:48 HKT/SGT
|
|
|
Fujitsu's AI-powered supply chain solution selected as transformative example of applied-AI technology by World Economic Forum
Jul 14, 2025 10:30 JST
|
|
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Jul 14, 2025 10:20 JST
|
|
|
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
|
|
|
Bluemount Holdings Limited Announces Pricing of $5.5 Million Initial Public Offering
Jul 11, 2025 08:28 HKT/SGT
|
|
|
ZA Miner Launches AI-Powered Bitcoin Mining Contracts, Marking Milestone in Cloud Mining Innovation
Jul 11, 2025 07:00 HKT/SGT
|
|
|
XDS Datacentres and ICS Arabia partner to launch landmark 10MW Immersive Cooling Data Center in KSA
Jul 11, 2025 06:00 HKT/SGT
|
|
|
Alpaca Network Announces Launch of Modelz: The First Decentralized Exchange for AI Models
Jul 10, 2025 23:00 HKT/SGT
|
|
|
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
|
|
|
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
|
|
|
The 10th Quam IR Awards was Successfully Held
Jul 10, 2025 15:12 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|